

The map of the T Cell is being
drawn with T Cell Diagnostics'

TCR T CELL RECEPTOR ANTIBODIES

FIRST TCR ANTIBODIES

Since T Cell Diagnostics developed the technology for TCR mapping in 1986, more researchers have trusted their studies to our antibody products than any others. In fact, T Cell Diagnostics' antibodies are referenced in more than 100 reports published in the world's most respected scientific journals.

MOST TCR ANTIBODIES

The research community knows that T Cell Diagnostics offers the largest selection of antibodies available today and will continue to develop monoclonals to explore important variable region specificities. After all, we've built our company on it.

BEST TCR ANTIBODIES

T Cell Diagnostics offers antibodies to both alpha beta and gamma delta TCR variable regions, with protocols for flow cytometry, immunochemical staining, immunoprecipitation, western blots and mitogen studies. And our antibodies are supplied liquid, ready to use, in purified or FITC conjugated formats, in convenient test size volumes. Same day shipping is available.

To protect your valuable research investment, look for the first, biggest, and best TCR antibody manufacturer.



For more information and a complimentary diskette containing more than 100 published references citing T Cell Diagnostics TCR antibodies, call: (800) 624-4021 or (617) 521-1410 or Fax: (617) 521-1420.

T Cell Diagnostics, Inc., 30 Sidney St., Cambridge, MA 02139

D.C.# 462.0

HELPING YOU EXPLORE THE IMMUNE RESPONSE

Research Use Only. Not for use in Diagnostic procedures

Circle No. 9 on Readers' Service Card

Custom Transgenic Rat and Mouse Production



- Transgenic Mice and Rats Guaranteed
- Mice Delivered in Less Than 12 Weeks
- Proven Capability with Over 500 Genes
- Certified Murine Pathogen Free Animal Colony
- Shipments to Locations Worldwide

TRANSGENIC RAT PRODUCTION NOW AVAILABLE

DNX is the exclusive licensee to U.S. Patent
#4,873,191 DNA Pronuclear Microinjection



DNX - Transgenic Services

303B College Road East
Princeton Forrestal Ctr.
Princeton, NJ 08540

(609) 520-0300

Circle No. 8 on Readers' Service Card

immunizing with a pool of solubilized class I and class II HLA antigens, including those shared with gp120. Such an approach would maximize the number of immunizing determinants and minimize the risk of infecting the prospective vaccinee with blood-borne viruses.

Gene M. Shearer

Mario Clerici

Experimental Immunology Branch,
National Cancer Institute,
National Institutes of Health,
Bethesda, MD 20892

Angus Dalgleish

Department of Cellular and Medical Sciences,
St. Georges Hospital Medical School,
London SW17 0RE,
United Kingdom

References

1. J. Stott, *Nature* 353, 393 (1991).
2. A. J. Langlois et al., *AIDS Res. Hum. Retrovir.* 8, 1669 (1993).
3. A. J. Langlois, K. J. Weinhold, T. J. Matthews, M. L. Greenberg, D. P. Bolognesi, *Science* 255, 292 (1992); B. F. Haynes, *ibid.* 260, 1279 (1993).
4. L. Authur et al., *ibid.* 258, 1935 (1992).
5. W. L. Chan et al., *J. Exp. Med.* 176, 1203 (1992).
6. F. A. Plummer et al., *IXth Int. Conf. AIDS* (abstr. WS-A07-3) (1993).
7. E. F. Hounsell et al., *Mol. Aspects Med.* 12, 283 (1991); H. D. Habeshaw, E. F. Hounsell, A. G. Dalgleish, *Immunol. Today* 13, 207 (1992); R. Blackburn et al., *Adv. Exp. Med. Biol.* 303, 63 (1991).
8. A. Beretta et al., *Eur. J. Immunol.* 23, 2016 (1993).
9. — et al., *IXth Int. Conf. AIDS* (abstr. WS-A13-1) (1993).
10. M. Clerici et al., *Eur. J. Immunol.* 23, 2022 (1993).
11. A. B. Sabin, *Proc. Natl. Acad. Sci. U.S.A.* 89, 8852 (1992).
12. G. Opelz, *Transpl. Proc.* 19, 149 (1987); J. J. van Rood and F. H. J. Claas, *Science* 248, 1388 (1990); E. van Twijver et al., *N. Engl. J. Med.* 325, 1210 (1991).



A Magic Bullet Against AIDS?

A prophylactic vaccine against infection by the human immunodeficiency virus (HIV) is years away at best (1) and once developed will face formidable obstacles to successful deployment (2). Although many researchers are promoting behavioral interventions to diminish the spread of acquired immune deficiency (AIDS), as noted in the news article by Jon Cohen, the prevailing attitude is that such interventions—the use of condoms or the sterilization of drug injection equipment, for example—are inherently inferior to the “magic bullets” proffered by biomedical science. The veracity of this proposition, however, has received little critical examination.

In order to demonstrate the importance of behavioral risk reduction, one can pose the question, How large a proportion, ϕ , of the sexually active population would

need to be *successfully* vaccinated to decrease the rate of HIV reproduction to the same as that attained by the universal (100%) use of condoms? [The reproductive rate (3) is essentially the number of secondary infections arising from each primary infection early in the epidemic.] If each act of sexual intercourse capable of transmitting the virus constitutes an independent Bernoulli trial (4), then ϕ can be approximated by

$$\phi = 1 - \frac{1 - (1 - \alpha\epsilon)^c}{1 - (1 - \alpha)^c}$$

where α denotes the infectivity of HIV (that is, the per-contact probability of transmission from an infected to an uninfected partner), ϵ denotes the condom failure rate, and c is the number of sexual encounters during a sexual relationship of average duration.

If one assumes that $c\alpha$ is not too large, then $(1 - \alpha)^c \approx 1 - c\alpha$, hence

$$\phi = 1 - \epsilon$$

In other words, if condoms are 90% effective in preventing the transmission of HIV, then 90% of the population would have to be successfully vaccinated for society to get the same benefit (the same reduction in the spread of AIDS) as it would from the conscientious use of condoms (5).

Although precise estimates of the failure rate of condoms with respect to HIV transmission are difficult to obtain (6), it appears that the commonly cited figure of 10% is conservative; recent studies indicate a 2% failure rate when condoms are properly used (7). If condoms are, in fact, about 90% effective, it seems reasonable to question whether *any* vaccine could protect the population against HIV infection as well as the consistent use of condoms; θ is the proportion of the population that is *successfully* vaccinated and is therefore the product of the percentage vaccinated and the efficacy of the vaccine. Thus, unless vaccination of the entire population could be ensured, even a 90% effective vaccine would not equal the protection offered by the consistent use of condoms.

The above analysis is oversimplified and assumes a rather unrealistic rate of condom usage (100%). Nevertheless, the take-home message should be clear: biomedical solutions alone cannot defeat AIDS; only humans can. Thus, our prevention "eggs" should be distributed into several "baskets," including producing better condoms and facilitating their use.

Steven D. Pinkerton

Paul R. Abramson

Department of Psychology,
University of California,
Los Angeles, CA 90024-1563

References and Notes

1. B. F. Haynes, *Science* **260**, 1279 (1993).
2. S. D. Pinkerton and P. R. Abramson, *Eval. Rev.*, in press.
3. R. M. May and R. M. Anderson, *Nature* **326**, 137 (1987); S. D. Pinkerton and P. R. Abramson, in preparation.
4. S. D. Pinkerton and P. R. Abramson, *Eval. Rev.* **17**, 504 (1993).
5. Under conditions of high infectivity, or where this approximation otherwise fails, $\theta < 1 - \epsilon$.
6. M. F. Goldsmith, *J. Am. Med. Assoc.* **257**, 2261 (1987).
7. Centers for Disease Control, *Morb. Mortal. Wkly. Rep.* **42**, 589 (1993).

Transportation Costs and the National Debt

In buying a car, one considers many things, including price, comfort, appearance, and a preference for one make rather than another. A consideration in the mind of many purchasers is miles attainable per gallon of fuel, a number that is clearly posted on the price sticker of each new vehicle. What is really important, however, is cents per mile; in other words, how much does it actually cost to own and operate an automobile?

The answer can be readily obtained from *Motor Vehicles Facts and Figures* (1). In this study, ownership costs are based on a 6-year or 60,000-mile retention cycle. All costs, including those for gas and oil, maintenance, tires, insurance, license, registration, depreciation, and finance charges, are included. In 1992, the national average total cost per mile was 45.77¢, which included 5.2¢ per mile for gas and 0.8¢ per mile for oil change charges. Thus, the net cost for gasoline was about 5¢ per mile or about 10% of the total transportation cost of 45.77¢ per mile. This fuel cost is the lowest in recent history and reflects progress in engine efficiency achieved over the last 20 years (2): for all registered cars, the average miles per gallon was 13.3 in 1973 and 17.1 in 1983; the preliminary data indicate 21.7 for 1991.

The impact of an additional gasoline tax should now be considered. The current congressional proposal, after long and tedious debate, centers at about 5¢ per gallon. The effect of this tax on transportation cost would be 5¢ divided by 21.7 (the current average miles per gallon), which equals a 0.23¢-per-mile increase. Thus, instead of 45.77¢ per mile, the new transportation cost would be 46.0¢ per mile, an increase of only 0.5%. The same 5¢ gasoline tax increase, when based on the 1991 consumption of 120 billion gallons of gasoline (3), would bring in \$6 billion per year. Thus, in the major drive

QUALITY ANTIBODIES

FOR

SIGNAL TRANSDUCTION RESEARCH

Monoclonal antibodies to:

— Map kinases (ERKs), Map ERK kinases (MEKs), and ERK kinase kinase (MEK kinase)

— SH2 containing proteins: GRB2, SHC, PI3 kinase, GAP, VAV, NCK, PLC γ , ISGF3, PTP1C, PTP1D


— Receptor tyr. kinases: EGF, insulin, PDGF, FGF receptors

— Phosphotyrosine: monoclonal PY20, polyclonal, recombinant antibody RC20


— Many other signalling proteins

Don't compromise your research with inferior antibodies!

Anti-ISGF3 Mab Western Blot



Affordably priced under \$200



Transduction
Laboratories

1-800-227-4063

Lexington, Kentucky

Tel: 606-277-1399

Fax: 606-276-2251

In Europe, contact:
Affiniti Research Products
Tel: (44) 602-436100
Fax: (44) 602-436300

In Japan, contact:
Funakoshi Co., LTD.
Tel: 81-3-5684-1622
Fax: 81-3-5684-1633

Circle No. 23 on Readers' Service Card